BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

232 related articles for article (PubMed ID: 31684910)

  • 1. SMAD4 Y353C promotes the progression of PDAC.
    Wang Z; Li Y; Zhan S; Zhang L; Zhang S; Tang Q; Li M; Tan Z; Liu S; Xing X
    BMC Cancer; 2019 Nov; 19(1):1037. PubMed ID: 31684910
    [TBL] [Abstract][Full Text] [Related]  

  • 2. MicroRNA-301a-3p promotes pancreatic cancer progression via negative regulation of SMAD4.
    Xia X; Zhang K; Cen G; Jiang T; Cao J; Huang K; Huang C; Zhao Q; Qiu Z
    Oncotarget; 2015 Aug; 6(25):21046-63. PubMed ID: 26019136
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Immunohistochemically detected expression of 3 major genes (CDKN2A/p16, TP53, and SMAD4/DPC4) strongly predicts survival in patients with resectable pancreatic cancer.
    Oshima M; Okano K; Muraki S; Haba R; Maeba T; Suzuki Y; Yachida S
    Ann Surg; 2013 Aug; 258(2):336-46. PubMed ID: 23470568
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Localisation of PGK1 determines metabolic phenotype to balance metastasis and proliferation in patients with SMAD4-negative pancreatic cancer.
    Liang C; Shi S; Qin Y; Meng Q; Hua J; Hu Q; Ji S; Zhang B; Xu J; Yu XJ
    Gut; 2020 May; 69(5):888-900. PubMed ID: 31611300
    [TBL] [Abstract][Full Text] [Related]  

  • 5. SMAD4 loss triggers the phenotypic changes of pancreatic ductal adenocarcinoma cells.
    Chen YW; Hsiao PJ; Weng CC; Kuo KK; Kuo TL; Wu DC; Hung WC; Cheng KH
    BMC Cancer; 2014 Mar; 14():181. PubMed ID: 24625091
    [TBL] [Abstract][Full Text] [Related]  

  • 6. SMAD4 genetic alterations predict a worse prognosis in patients with pancreatic ductal adenocarcinoma.
    Singh P; Srinivasan R; Wig JD
    Pancreas; 2012 May; 41(4):541-6. PubMed ID: 22504380
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinicopathological significance of SMAD4 loss in pancreatic ductal adenocarcinomas: a systematic review and meta-analysis.
    Wang JD; Jin K; Chen XY; Lv JQ; Ji KW
    Oncotarget; 2017 Mar; 8(10):16704-16711. PubMed ID: 28053288
    [TBL] [Abstract][Full Text] [Related]  

  • 8. TGFB1-induced autophagy affects the pattern of pancreatic cancer progression in distinct ways depending on SMAD4 status.
    Liang C; Xu J; Meng Q; Zhang B; Liu J; Hua J; Zhang Y; Shi S; Yu X
    Autophagy; 2020 Mar; 16(3):486-500. PubMed ID: 31177911
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A comprehensive examination of Smad4, Smad6 and Smad7 mRNA expression in pancreatic ductal adenocarcinoma.
    Singh P; Wig JD; Srinivasan R; Radotra BD
    Indian J Cancer; 2011; 48(2):170-4. PubMed ID: 21768661
    [TBL] [Abstract][Full Text] [Related]  

  • 10. SMAD4: a predictive marker of PDAC cell permissiveness for oncolytic infection with parvovirus H-1PV.
    Dempe S; Stroh-Dege AY; Schwarz E; Rommelaere J; Dinsart C
    Int J Cancer; 2010 Jun; 126(12):2914-27. PubMed ID: 19856310
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Phosphatase PPM1A is a novel prognostic marker in pancreatic ductal adenocarcinoma.
    Fan J; Yang MX; Ouyang Q; Fu D; Xu Z; Liu X; Mino-Kenudson M; Geng J; Tang F
    Hum Pathol; 2016 Sep; 55():151-8. PubMed ID: 27195906
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Upregulated SMAD3 promotes epithelial-mesenchymal transition and predicts poor prognosis in pancreatic ductal adenocarcinoma.
    Yamazaki K; Masugi Y; Effendi K; Tsujikawa H; Hiraoka N; Kitago M; Shinoda M; Itano O; Tanabe M; Kitagawa Y; Sakamoto M
    Lab Invest; 2014 Jun; 94(6):683-91. PubMed ID: 24709776
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pattern of Invasion in Human Pancreatic Cancer Organoids Is Associated with Loss of SMAD4 and Clinical Outcome.
    Huang W; Navarro-Serer B; Jeong YJ; Chianchiano P; Xia L; Luchini C; Veronese N; Dowiak C; Ng T; Trujillo MA; Huang B; Pflüger MJ; Macgregor-Das AM; Lionheart G; Jones D; Fujikura K; Nguyen-Ngoc KV; Neumann NM; Groot VP; Hasanain A; van Oosten AF; Fischer SE; Gallinger S; Singhi AD; Zureikat AH; Brand RE; Gaida MM; Heinrich S; Burkhart RA; He J; Wolfgang CL; Goggins MG; Thompson ED; Roberts NJ; Ewald AJ; Wood LD
    Cancer Res; 2020 Jul; 80(13):2804-2817. PubMed ID: 32376602
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Combination of KRAS and SMAD4 mutations in formalin-fixed paraffin-embedded tissues as a biomarker for pancreatic cancer.
    Yokose T; Kitago M; Matsuda S; Sasaki Y; Masugi Y; Nakamura Y; Shinoda M; Yagi H; Abe Y; Oshima G; Hori S; Yusuke F; Nakano Y; Endo Y; Abe K; Tokino T; Kitagawa Y
    Cancer Sci; 2020 Jun; 111(6):2174-2182. PubMed ID: 32314446
    [TBL] [Abstract][Full Text] [Related]  

  • 15. High expression of AFAP1-AS1 is associated with poor survival and short-term recurrence in pancreatic ductal adenocarcinoma.
    Ye Y; Chen J; Zhou Y; Fu Z; Zhou Q; Wang Y; Gao W; Zheng S; Zhao X; Chen T; Chen R
    J Transl Med; 2015 Apr; 13():137. PubMed ID: 25925763
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Loss of Trefoil Factor 2 From Pancreatic Duct Glands Promotes Formation of Intraductal Papillary Mucinous Neoplasms in Mice.
    Yamaguchi J; Mino-Kenudson M; Liss AS; Chowdhury S; Wang TC; Fernández-Del Castillo C; Lillemoe KD; Warshaw AL; Thayer SP
    Gastroenterology; 2016 Dec; 151(6):1232-1244.e10. PubMed ID: 27523981
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cadherin-1 and cadherin-3 cooperation determines the aggressiveness of pancreatic ductal adenocarcinoma.
    Siret C; Dobric A; Martirosyan A; Terciolo C; Germain S; Bonier R; Dirami T; Dusetti N; Tomasini R; Rubis M; Garcia S; Iovanna J; Lombardo D; Rigot V; André F
    Br J Cancer; 2018 Feb; 118(4):546-557. PubMed ID: 29161242
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Integration of Bioinformatics Resources Reveals the Therapeutic Benefits of Gemcitabine and Cell Cycle Intervention in SMAD4-Deleted Pancreatic Ductal Adenocarcinoma.
    Hsieh YY; Liu TP; Chou CJ; Chen HY; Lee KH; Yang PM
    Genes (Basel); 2019 Sep; 10(10):. PubMed ID: 31569425
    [TBL] [Abstract][Full Text] [Related]  

  • 19. AGR2 is a SMAD4-suppressible gene that modulates MUC1 levels and promotes the initiation and progression of pancreatic intraepithelial neoplasia.
    Norris AM; Gore A; Balboni A; Young A; Longnecker DS; Korc M
    Oncogene; 2013 Aug; 32(33):3867-76. PubMed ID: 22945649
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Stem cell marker nestin is critical for TGF-β1-mediated tumor progression in pancreatic cancer.
    Su HT; Weng CC; Hsiao PJ; Chen LH; Kuo TL; Chen YW; Kuo KK; Cheng KH
    Mol Cancer Res; 2013 Jul; 11(7):768-79. PubMed ID: 23552743
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.